Nanomedicines for Pulmonary Drug Delivery: Overcoming Barriers in the Treatment of Respiratory Infections and Lung Cancer
The pulmonary route for drug administration has garnered a great deal of attention in therapeutics for treating respiratory disorders. It allows for the delivery of drugs directly to the lungs and, consequently, the maintenance of high concentrations at the action site and a reduction in systemic ad...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/16/12/1584 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846103184654729216 |
|---|---|
| author | Raquel Fernández-García Ana I. Fraguas-Sánchez |
| author_facet | Raquel Fernández-García Ana I. Fraguas-Sánchez |
| author_sort | Raquel Fernández-García |
| collection | DOAJ |
| description | The pulmonary route for drug administration has garnered a great deal of attention in therapeutics for treating respiratory disorders. It allows for the delivery of drugs directly to the lungs and, consequently, the maintenance of high concentrations at the action site and a reduction in systemic adverse effects compared to other routes, such as oral or intravenous. Nevertheless, the pulmonary administration of drugs is challenging, as the respiratory system tries to eliminate inhaled particles, being the main responsible mucociliary escalator. Nanomedicines represent a primary strategy to overcome the limitations of this route as they can be engineered to prolong pulmonary retention and avoid their clearance while reducing drug systemic distribution and, consequently, systemic adverse effects. This review analyses the use of pulmonary-administered nanomedicines to treat infectious diseases affecting the respiratory system and lung carcinoma, two pathologies that represent major health threats. |
| format | Article |
| id | doaj-art-f649f170387449d2bcba6ce696f30bbd |
| institution | Kabale University |
| issn | 1999-4923 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj-art-f649f170387449d2bcba6ce696f30bbd2024-12-27T14:46:35ZengMDPI AGPharmaceutics1999-49232024-12-011612158410.3390/pharmaceutics16121584Nanomedicines for Pulmonary Drug Delivery: Overcoming Barriers in the Treatment of Respiratory Infections and Lung CancerRaquel Fernández-García0Ana I. Fraguas-Sánchez1School of Pharmacy, University of Nottingham, University Park, Nottingham NG7 2RD, UKDepartment of Pharmaceutics and Food Technology, School of Pharmacy, Complutense University, 28040 Madrid, SpainThe pulmonary route for drug administration has garnered a great deal of attention in therapeutics for treating respiratory disorders. It allows for the delivery of drugs directly to the lungs and, consequently, the maintenance of high concentrations at the action site and a reduction in systemic adverse effects compared to other routes, such as oral or intravenous. Nevertheless, the pulmonary administration of drugs is challenging, as the respiratory system tries to eliminate inhaled particles, being the main responsible mucociliary escalator. Nanomedicines represent a primary strategy to overcome the limitations of this route as they can be engineered to prolong pulmonary retention and avoid their clearance while reducing drug systemic distribution and, consequently, systemic adverse effects. This review analyses the use of pulmonary-administered nanomedicines to treat infectious diseases affecting the respiratory system and lung carcinoma, two pathologies that represent major health threats.https://www.mdpi.com/1999-4923/16/12/1584pulmonary deliverynanomedicineinfectious diseasestuberculosiscancerdry powder inhalers |
| spellingShingle | Raquel Fernández-García Ana I. Fraguas-Sánchez Nanomedicines for Pulmonary Drug Delivery: Overcoming Barriers in the Treatment of Respiratory Infections and Lung Cancer Pharmaceutics pulmonary delivery nanomedicine infectious diseases tuberculosis cancer dry powder inhalers |
| title | Nanomedicines for Pulmonary Drug Delivery: Overcoming Barriers in the Treatment of Respiratory Infections and Lung Cancer |
| title_full | Nanomedicines for Pulmonary Drug Delivery: Overcoming Barriers in the Treatment of Respiratory Infections and Lung Cancer |
| title_fullStr | Nanomedicines for Pulmonary Drug Delivery: Overcoming Barriers in the Treatment of Respiratory Infections and Lung Cancer |
| title_full_unstemmed | Nanomedicines for Pulmonary Drug Delivery: Overcoming Barriers in the Treatment of Respiratory Infections and Lung Cancer |
| title_short | Nanomedicines for Pulmonary Drug Delivery: Overcoming Barriers in the Treatment of Respiratory Infections and Lung Cancer |
| title_sort | nanomedicines for pulmonary drug delivery overcoming barriers in the treatment of respiratory infections and lung cancer |
| topic | pulmonary delivery nanomedicine infectious diseases tuberculosis cancer dry powder inhalers |
| url | https://www.mdpi.com/1999-4923/16/12/1584 |
| work_keys_str_mv | AT raquelfernandezgarcia nanomedicinesforpulmonarydrugdeliveryovercomingbarriersinthetreatmentofrespiratoryinfectionsandlungcancer AT anaifraguassanchez nanomedicinesforpulmonarydrugdeliveryovercomingbarriersinthetreatmentofrespiratoryinfectionsandlungcancer |